Company news

Lantheus Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

January 27, 2025

Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market

January 12, 2025

Lantheus Announces Share Repurchase Program

November 19, 2024

Lantheus to Present at the Jefferies London Healthcare Conference

November 12, 2024

Lantheus Continues to Commend CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY’s Blockbuster Status for 2025

November 10, 2024

Lantheus Reports Third Quarter 2024 Financial Results

November 5, 2024

Lantheus Applauds CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care

November 3, 2024

Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8: 00 a.m. Eastern Time

October 22, 2024

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

September 14, 2024

Lantheus Appoints Julie Eastland as New Board Member

September 4, 2024

Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

August 27, 2024

Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

August 19, 2024

Lantheus Reports Second Quarter 2024 Financial Results

July 30, 2024

Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8: 00 a.m. Eastern Time

July 16, 2024

Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer’s Disease

July 14, 2024

Lantheus Welcomes CMS’ Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access

July 9, 2024

Lantheus Appoints Jamie Spaeth as Chief People Officer

July 7, 2024

Lantheus Acquires Global Rights to Life Molecular Imaging’s Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers

June 26, 2024

Lantheus’ AI-Enabled aPROMISE Now Available on Siemens Healthineers’ syngo.via platform

June 2, 2024

Lantheus to Present at the William Blair 44th Annual Growth Stock Conference

May 27, 2024

Lantheus Announces Executive Appointments to Accelerate Innovation

May 14, 2024

Lantheus Reports First Quarter 2024 Financial Results

May 1, 2024

Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8: 00 a.m. Eastern Time

April 17, 2024

Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024

March 4, 2024

Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients

March 3, 2024

Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer

February 27, 2024

Lantheus to Present at the TD Cowen 44th Annual Health Care Conference

February 25, 2024

Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results

February 21, 2024

Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging

February 12, 2024

Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8: 00 a.m. Eastern Time

February 7, 2024

Lantheus Announces CEO Succession Plan

January 22, 2024

Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)

January 10, 2024

Lantheus Reports Preliminary Fiscal Year 2023 Revenue

January 8, 2024

Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics

January 8, 2024

Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer

December 17, 2023

Lantheus Reports Third Quarter 2023 Financial Results

November 1, 2023

Lantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on November 2, 2023, at 8: 00 a.m. Eastern Time

October 18, 2023

Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting

August 31, 2023

Lantheus to Present at the Wells Fargo Healthcare Conference

August 30, 2023

Lantheus Reports Second Quarter 2023 Financial Results

August 2, 2023

Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty

August 2, 2023

Lantheus to Host Second Quarter 2023 Earnings Conference Call and Webcast on August 3, 2023, at 8: 00 a.m. Eastern Time

July 19, 2023

Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

June 11, 2023

Lantheus to Present at the Jefferies Healthcare Conference

May 31, 2023

Lantheus Announces Payment to Contingent Value Rights (CVR) Holders of $99.7 million or $1.15 per CVR

May 22, 2023

Lantheus Reports First Quarter 2023 Financial Results

May 3, 2023

Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

April 23, 2023

Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

April 23, 2023

Lantheus to Host First Quarter 2023 Earnings Conference Call and Webcast on May 4, 2023, at 8: 00 a.m. Eastern Time

April 19, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 17 decks. Every deck is listed under its year.